VPA25579/004/001

Avishield IB GI-13, lyophilisate for oculonasal suspension/use in drinking water for chickens

Variation	Summary	Date
Vet - C9	VNRA - Vet - C9 - - Vet - C9 - Editorial changes to SPC, package leaflet or labelling if inclusion in an upcoming procedure is not possible	10/09/26
Vet - C1	VNRA - Vet - C1 - - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	01/09/26
Vet - C6	VNRA - Vet - C6 - - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex	01/09/26
Vet - G.I.18	VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	30/04/26
Vet - G.I.4	VRA-S - Vet - G.I.4 - - Vet - G.I.4 - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data.	30/04/26
Vet - F.II.b.5 z)	VRA-R - Vet - F.II.b.5 z) - - Vet - F.II.b.5 z) - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	14/10/25
Vet - F.II.b.5 z)	VRA-R - Vet - F.II.b.5 z) - - Vet - F.II.b.5 z) - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	14/10/25
Vet - F.II.b.5 z)	VRA-R - Vet - F.II.b.5 z) - - Vet - F.II.b.5 z) - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	14/10/25
Vet - F.II.b.5 z)	VRA-R - Vet - F.II.b.5 z) - - Vet - F.II.b.5 z) - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	14/10/25
Vet - F.II.b.5 z)	VRA-R - Vet - F.II.b.5 z) - - Vet - F.II.b.5 z) - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	14/10/25
Vet - F.II.f.1 a) 5.	VRA-R - Vet - F.II.f.1 a) 5. - a) Extension of the shelf life of the finished product 5. Extension of the shelf-life of a biological/immunological medicinal product in accordance with an approved stability protocol. - F.II.f.1 a) 5. Quality	02/04/24

	Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Extension of the shelf life of the finished product - Extension of the shelf-life of a biological/immunological medicinal product in accordance with an approved stability protocol.	
Vet - F.I.a.2 z)	VRA-R - Vet - F.I.a.2 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.I.a.2 z) Quality Changes - Active Substance - Manufacture - Changes in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	24/03/23
B.I.b.1.d	IA - B.I.b.1.d - d) Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) - B.I.b.1.d - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	24/03/22
B.I.b.2.e	IB - B.I.b.2.e - e) Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - B.I.b.2.e - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate	24/03/22
B.I.b.2.e	IB - B.I.b.2.e - e) Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - B.I.b.2.e - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate	24/03/22
B.II.d.1.f	II - B.II.d.1.f - f) Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product - B.II.d.1.f - QUALITY CHANGES - FINISHED PRODUCT - Control of finished product - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product	24/03/22
C.I.4	II - C.I.4 - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - C.I.4 - SAFETY, EFFICACY, PHARMACOVIGILANCE	10/03/22

	CHANGES - HUMAN AND VETERINARY MEDICINAL PRODUCTS - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data	